Radius Health Inc (NASDAQ:RDUS) Given Consensus Recommendation of “Buy” by Analysts

Radius Health Inc (NASDAQ:RDUS) has been given an average recommendation of “Buy” by the ten analysts that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $35.00.

A number of research firms recently commented on RDUS. BidaskClub raised Radius Health from a “hold” rating to a “buy” rating in a research report on Wednesday, June 19th. Zacks Investment Research upgraded Radius Health from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Monday, May 6th. Citigroup restated a “neutral” rating and issued a $24.00 target price on shares of Radius Health in a research note on Thursday, May 30th. HC Wainwright restated a “hold” rating on shares of Radius Health in a research note on Thursday, May 9th. Finally, Cowen restated a “hold” rating on shares of Radius Health in a research note on Wednesday, May 8th.

In other Radius Health news, VP Joseph Francis Kelly purchased 2,000 shares of the stock in a transaction on Friday, May 10th. The shares were purchased at an average price of $21.43 per share, with a total value of $42,860.00. Following the acquisition, the vice president now directly owns 5,000 shares in the company, valued at approximately $107,150. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Willard H. Dere sold 1,680 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $22.22, for a total value of $37,329.60. Following the completion of the sale, the director now directly owns 8,620 shares in the company, valued at approximately $191,536.40. The disclosure for this sale can be found here. Company insiders own 4.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Bank of Montreal Can raised its stake in Radius Health by 231.3% during the fourth quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 1,078 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Radius Health by 75.8% during the fourth quarter. Rhumbline Advisers now owns 61,939 shares of the biopharmaceutical company’s stock valued at $1,021,000 after purchasing an additional 26,702 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Radius Health by 25.3% during the fourth quarter. California Public Employees Retirement System now owns 73,700 shares of the biopharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 14,900 shares in the last quarter. BB Biotech AG boosted its position in shares of Radius Health by 1.8% during the fourth quarter. BB Biotech AG now owns 6,710,276 shares of the biopharmaceutical company’s stock valued at $110,652,000 after purchasing an additional 120,000 shares in the last quarter. Finally, Knott David M boosted its position in shares of Radius Health by 251.2% during the fourth quarter. Knott David M now owns 77,269 shares of the biopharmaceutical company’s stock valued at $1,274,000 after purchasing an additional 55,269 shares in the last quarter.

Shares of NASDAQ:RDUS opened at $24.36 on Friday. The company has a debt-to-equity ratio of 6.75, a current ratio of 5.16 and a quick ratio of 5.04. Radius Health has a twelve month low of $12.81 and a twelve month high of $30.54. The stock’s 50 day moving average price is $21.96. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.99 and a beta of 0.99.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.01. The business had revenue of $29.84 million during the quarter, compared to analyst estimates of $35.35 million. Radius Health had a negative return on equity of 233.12% and a negative net margin of 176.84%. Radius Health’s quarterly revenue was up 105.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.11) EPS. As a group, research analysts anticipate that Radius Health will post -3.59 EPS for the current year.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Featured Story: What are the risks of holding treasury bonds?

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.